Maintenance Therapy for Advanced Lung Cancer: Who, What, and When?

被引:13
作者
Gerber, David E. [1 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Harold C Simmons Canc Ctr, Dallas, TX 75390 USA
关键词
PHASE-III TRIAL; ONCOLOGY-GROUP; 4599; TREATMENT RATIONALE; RANDOMIZED-TRIAL; 1ST-LINE TREATMENT; COST-EFFECTIVENESS; COLORECTAL-CANCER; PROSTATE-CANCER; SUPPORTIVE CARE; STAGE-IIIB;
D O I
10.1200/JCO.2012.48.5201
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A 60-year-old woman with hypertension, dyslipidemia, and 35-pack-year smoking history is referred for treatment of advanced non-small-cell lung cancer (NSCLC). She initially presented after a transient ischemic attack, when a chest radiograph demonstrated a right lung mass. Computed tomography (CT) of the chest revealed a 5-cm right upper lobe mass, without mediastinal adenopathy, and a 6-cm cystic mass in the spleen. Additional imaging showed no brain metastasis. Endobronchial ulstrasound-guided core biopsies of the lung mass and ipsilateral mediastinal nodes confirmed a poorly differentiated non-small-cell carcinoma. Immunohistochemical stains were positive for napsin A and thyroid transcription factor 1, suggestive of adenocarcinoma (Fig 1). Molecular analysis identified a KRAS G12C mutation. A positron emission tomography (PET) -CT scan demonstrated [F-18]fluorodeoxyglucose uptake in the right upper lobe mass and splenic lesion (Fig 2A). CT-guided fine-needle aspiration of the splenic lesion was performed and revealed metastatic carcinoma, consistent with the lung primary. Treatment with carboplatin plus pemetrexed was initiated, without bevacizumab because of the recent transient ischemic attack; carboplatin was selected over cisplatin because of similar concerns. The patient received two cycles of chemotherapy without complications, and repeat imaging showed decrease in size of the lung mass and splenic lesion (Figs 2B and 2C). After four cycles of chemotherapy, a chest CT showed ongoing response (Fig 2D). Her Eastern Cooperative Oncology Group performance status remained 0.
引用
收藏
页码:2983 / 2990
页数:8
相关论文
共 43 条
[1]  
[Anonymous], J CLIN ONCOL S
[2]   Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis [J].
Ardizzoni, Andrea ;
Boni, Luca ;
Tiseo, Marcello ;
Fossella, Frank V. ;
Schiller, Joan H. ;
Paesmans, Marianne ;
Radosavljevic, Davorin ;
Paccagnella, Adriano ;
Zatloukal, Petr ;
Mazzanti, Paola ;
Bisset, Donald ;
Rosell, Rafael .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (11) :847-857
[3]   Cisplatin versus carboplatin for patients with metastatic non-small-cell lung cancer - An old rivalry renewed [J].
Azzoli, Christopher G. ;
Kris, Mark G. ;
Pfister, David G. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (11) :828-829
[4]   Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: AVAPERL (MO22089) [J].
Barlesi, Fabrice ;
Scherpereel, Arnaud ;
Rittmeyer, Achim ;
Pazzola, Antonio ;
Tur, Neus Ferrer ;
Kim, Joo-Hang ;
Ahn, Myung-Ju ;
Aerts, Joachim G. J. V. ;
Gorbunova, Vera ;
Vikstrom, Anders ;
Wong, Elaine K. ;
Perez-Moreno, Pablo ;
Mitchell, Lada ;
Groen, Harry J. M. .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (24) :3004-+
[5]   Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation [J].
Belani, CP ;
Barstis, J ;
Perry, MC ;
La Rocca, RV ;
Nattam, SR ;
Rinaldi, D ;
Clark, R ;
Mills, GM .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) :2933-2939
[6]   Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial [J].
Bennouna, Jaafar ;
Sastre, Javier ;
Arnold, Dirk ;
Osterlund, Pia ;
Greil, Richard ;
Van Cutsem, Eric ;
von Moos, Roger ;
Maria Vieitez, Jose ;
Bouche, Olivier ;
Borg, Christophe ;
Steffens, Claus-Christoph ;
Alonso-Orduna, Vicente ;
Schlichting, Christoph ;
Reyes-Rivera, Irmarie ;
Bendahmane, Belguendouz ;
Andre, Thierry ;
Kubicka, Stefan .
LANCET ONCOLOGY, 2013, 14 (01) :29-37
[7]   Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial [J].
Brodowicz, T ;
Krzakowski, M ;
Zwitter, M ;
Tzekova, V ;
Ramlau, R ;
Ghilezan, N ;
Ciuleanuf, T ;
Cucevic, B ;
Gyurkovits, K ;
Ulsperger, E ;
Jassem, J ;
Grgic, M ;
Pinar, S ;
Szilasi, M ;
Wiltschke, C ;
Wagnerova, M ;
Oskina, N ;
Soldatenkova, V ;
Zielinski, C ;
Wenczl, M .
LUNG CANCER, 2006, 52 (02) :155-163
[8]   Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer [J].
Burger, Robert A. ;
Brady, Mark F. ;
Bookman, Michael A. ;
Fleming, Gini F. ;
Monk, Bradley J. ;
Huang, Helen ;
Mannel, Robert S. ;
Homesley, Howard D. ;
Fowler, Jeffrey ;
Greer, Benjamin E. ;
Boente, Matthew ;
Birrer, Michael J. ;
Liang, Sharon X. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (26) :2473-2483
[9]   Intermittent Androgen Deprivation for Locally Advanced and Metastatic Prostate Cancer: Results from a Randomised Phase 3 Study of the South European Uroncological Group [J].
Calais da Silva, Fernando E. C. ;
Bono, Aldo V. ;
Whelan, Peter ;
Brausi, Maurizio ;
Marques Queimadelos, Anton ;
Portillo Martin, Jose A. ;
Kirkali, Ziya ;
Calais da Silva, Fernando M. V. ;
Robertson, Chris .
EUROPEAN UROLOGY, 2009, 55 (06) :1269-1277
[10]   Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study [J].
Cappuzzo, Federico ;
Ciuleanu, Tudor ;
Stelmakh, Lilia ;
Cicenas, Saulius ;
Szczesna, Aleksandra ;
Juhasz, Erzsebet ;
Esteban, Emilio ;
Molinier, Olivier ;
Brugger, Wolfram ;
Melezinek, Ivan ;
Klingelschmitt, Gaelle ;
Klughammer, Barbara ;
Giaccone, Giuseppe .
LANCET ONCOLOGY, 2010, 11 (06) :521-529